New supramolecular alzheimers drugs

New supramolecular alzheimers drugs – Supramolecular chemistry could provide a new avenue in the treatment of Alzheimer’s disease, say scientists in China. The group demonstrates for the first time that supramolecular complexes can inhibit the aggregation of a peptide thought to cause Alzheimer’s disease.


Just to clarify: we don’t actually know what causes Alzheimer’s disease nor whether amyloid plaques are a cause or an effect. New drugs that focus on this etiology may not necessarily succeed, although if they do they would add to the evidence for plaques being a cause.